Cart
sales@molnova.com
E3 Ligand-Linker Conjugate 1
CAS No. 2098488-36-7
E3 Ligand-Linker Conjugate 1( Azido-Thalidomide | AzidoThalidomide | Azido Thalidomide )
Catalog No. M13317 CAS No. 2098488-36-7
E3 Ligand-Linker Conjugate 1 is an E3 ligand- Linker Conjugate for PROTAC.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 46 | Get Quote |
|
| 5MG | 75 | Get Quote |
|
| 10MG | 110 | Get Quote |
|
| 25MG | 177 | Get Quote |
|
| 50MG | 268 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameE3 Ligand-Linker Conjugate 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionE3 Ligand-Linker Conjugate 1 is an E3 ligand- Linker Conjugate for PROTAC.
-
DescriptionE3 Ligand-Linker Conjugate 1 is an E3 ligand- Linker Conjugate for PROTAC.
-
In Vitro——
-
In Vivo——
-
SynonymsAzido-Thalidomide | AzidoThalidomide | Azido Thalidomide
-
PathwayPROTACs
-
TargetE3 Ligase Ligand
-
RecptorE3 Ligase Ligand
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number2098488-36-7
-
Formula Weight428.405
-
Molecular FormulaC19H20N6O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 41 mg/mL (95.70 mM)
-
SMILESO=C(NCCCCN=[N+]=[N-])COC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O
-
Chemical NameN-(4-azidobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Schiedel M, et al. J Med Chem. 2017 Apr 17. doi: 10.1021/acs.jmedchem.6b01872.
molnova catalog
related products
-
E3 Ligand-Linker Con...
An E3 ligase ligand-linker conjugate for PROTAC.
-
(S,R,S)-AHPC-Me hydr...
(S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader.
-
Golcadomide
Golcadomide (CC-99282) is a orally active CRBN E3 ligase modulator that induces interactions between CRBN and its neo-substrate, recruiting the target disease-causing proteins and the E3 ubiquitin ligase.
